For example, pasireotide, which has been reported to be effective in treating GH/prolactin-secreting adenomas that developed in transgenic mice ubiquitously overexpressing the high mobility group family AT-hook2 (HMGA2) gene (25), has been used in Phase III clinical trials to treat acromegaly, in which pasireotide was effective in suppressing GH secretion to less than 2.5 μg/L with normalization of IGF-I levels and significant tumor reduction in approximately 75% of patients (27, 41). This evidence concerns the gene PRL and neoplasm.